Co-Diagnostics (NASDAQ: CODX) — Perfil da empresa, notícias e dados financeiros
Co-Diagnostics designs diagnostic solutions for infectious diseases, aiming to improve public health worldwide.
Co-Diagnostics
Co-Diagnostics (NASDAQ:CODX) specializes in designing and producing diagnostic solutions for diseases. Their operations focus on leveraging innovative technology to create diagnostics tests that are cost-effective, efficient, and reliable, addressing a myriad of infectious diseases globally. A significant part of their projects includes the development of tests for the detection of viruses, bacterial infections, and genetic mutations across various health sectors. Their objective is to improve public health through accessible diagnostic solutions, aiming to expand their reach in both developed and developing markets and adapt to emerging health challenges. Co-Diagnostics is committed to advancing healthcare standards and contributing to global disease control efforts.
Resumo
Operações
Produtos e/ou serviços de Co-Diagnostics
- Logix Smart COVID-19 Test, a PCR test for the detection of SARS-CoV-2 virus.
- Co-Dx PCR Home Platform, a portable, affordable home testing solution for various pathogens.
- Logix Smart Zika Virus Test, a qualitative test for the detection of Zika virus RNA.
- Logix Smart Malaria Test, designed to detect the Plasmodium parasite in patients.
- Co-Primer technology, enhancing the accuracy and speed of PCR diagnostic tests by reducing primer-dimer formation.
- Vector Smart NAM test, identifies mosquito-borne diseases like West Nile, St. Louis Encephalitis, and Western Equine Encephalitis.
equipe executiva do Co-Diagnostics
- Dwight H. EganChairman, CEO & President
- Richard David AbbottPresident
- Dan BohrerExecutive VP of Finance & Accounting and Principal Financial & Accounting Officer
- David NielsenChief Operating Officer
- Christopher ThurstonChief Technology Officer
- Wesley C. LindseyChief Scientific Officer
- Andrew BensonHead of Investor Relations
- Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic Alliances
- Seth EganChief Commercialization Officer & Strategy Officer
Principais indicadores financeiros
Resultados divulgados pela Co-Diagnostics, em USD.
- Cap. de mercado
- 3,9 mi
- Receita (TTM)
- 721,4 mil
- P/L
- —
- LPA (diluído, TTM)
- -26.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 622,5 mil | -31,3 mi | -46,9 mi | |
| 3,9 mi | -40,1 mi | -37,6 mi | |
| 6,8 mi | -42,7 mi | -35,3 mi | |
| 34,2 mi | -27 mi | -14,2 mi |